RIAN SENDS US A MESSAGE
When he’s not busy re-enacting movie scenes in his living room, Rian’s off having a blast with his best buddy . Like most kids their age, his best friend sees beyond Rian’s disease, always challenging his pal to strive to be the best he can be. There’s no doubt that he plays a huge role in Rian’s life.
Dynacure is a clinical-stage drug development company focused on improving the lives of patients with rare and orphan diseases. The Dynacure team leverages its proven track record in rare disease drug development to build a pipeline of novel drugs. Dynacure is developing DYN101, an investigational antisense medicine designed to modulate the expression of dynamin 2 for the treatment of Centronuclear Myopathies, with Ionis Pharmaceuticals. Dynacure is also building a complementary research portfolio targeting other orphan disorders.